Phase II Study of Combination Epitope Peptides with gemcitabine for Advanced/metastatic Pancreatic Cancer
Phase 2
- Conditions
- Advanced/metastatic Pancreatic Cancer
- Registration Number
- JPRN-UMIN000005301
- Lead Sponsor
- YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE Department of Digestive Surgery and Surgical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe heart diseases 2. Wish for pregnancy 3. Active infection 4. Steroid or immunosuppressive therapy 5. Allergy for using epitope peptides 6. Mental and nervous disorder 7. Massive pleural or abdominal effusions 8. Rapid growth of liver metastasis 9. Doctors opinion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Response rate Progression free survival Safety Disease control rate specific immune response